8 news items
BioLineRx Announces Clinical Trial Agreement with St. Jude Children's Research Hospital, Inc. to Evaluate Motixafortide for CD34+ Hematopoietic Stem Cell (HSC) Mobilization For Gene Therapy Applications in Sickle Cell Disease (SCD)
BLRX
30 May 24
financing, including any unexpected costs or delays in the commercial launch of APHEXDA; risks related to changes in healthcare laws, rules
BioLineRx Reports First Quarter 2024 Financial Results and Recent Corporate and Portfolio Updates
BLRX
28 May 24
unexpected costs or delays in the commercial launch of APHEXDA; risks related to changes in healthcare laws, rules and regulations
BioLineRx Announces Abstract on Pilot Study Data from Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer (PDAC) at American Society of Clinical Oncology (ASCO) 2024 Annual Meeting
BLRX
24 May 24
or delays in the commercial launch of APHEXDA; risks related to changes in healthcare laws, rules and regulations
BioLineRx Announces Receipt of Nasdaq Minimum Bid Price Notification
BLRX
17 May 24
unexpected costs or delays in the commercial launch of APHEXDA; risks related to changes in healthcare laws, rules and regulations
BioLineRx Announces Poster Presentation on Economic Model Data for APHEXDA® (motixafortide) as part of CD34+ Hematopoietic Stem Cell Mobilization in Patients with Multiple Myeloma at ISPOR 2024
BLRX
6 May 24
assessed the cost and healthcare resource utilization impacts of multiple apheresis attempts via a comparison between daily filgrastim (G-CSF) alone
marj4g p4npilhzn
BLRX
17 Apr 24
in healthcare laws, rules and regulations in the United States or elsewhere; competitive
819 3ckks5
ABVC
BACK
BLRX
26 Mar 24
: www.benzinga.com/money/best-healthcare-stocks/
This article was generated by Benzinga's automated content engine and reviewed by an editor.
y7aap96y8q274sdgrg9nfsnexuw9d6et1agxlmlblozpnn5cx4h2nh
BLRX
4 Mar 24
to changes in healthcare laws, rules and regulations in the United States or elsewhere
- Prev
- 1
- Next